肺动脉高压的治疗:近期进展与未来展望
本文综述肺动脉高压(PAH)的治疗方法与选择,总结细胞与分子机制及新兴可治疗通路,强调优化现有管理策略,并探讨延缓或逆转肺血管重构的新型疗法、患者作为研究伙伴的角色及临床试验创新。
要点
- PAH是可治疗的前毛细血管性肺高血压,但死亡率仍高,亟需变革性创新。
- 基础科学、随机对照试验、真实世界数据与指南共同推动了治疗进展。
- 未来方向包括靶向肺血管重构的疗法、患者参与研究和临床试验创新。
核心结论
- PAH治疗已取得显著进展,但死亡率仍高,亟需延缓或逆转肺血管重构的变革性疗法。
研究设计与样本
- 本文为系列综述,由临床医生、研究人员和一名PAH患者共同撰写。
主要发现
- PAH是由肺血管重构引起的严重但可治疗的前毛细血管性肺高血压。
- 基础科学发现、随机对照试验、真实世界数据研究和临床实践指南推动了治疗选择与结局的进步。
- 当前知识强调新兴可治疗通路和优化现有管理策略。
临床怎么用
- 强调基础到临床再到患者的无缝转化,优化当前管理策略并关注新兴治疗通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic science discoveries, randomised controlled trials, studies of real-world data, and the development of clinical practice guidelines, considerable progress has been made in the treatment options and outcomes for patients with PAH, underscoring the importance of seamless translation of information from bench to bedside and, ultimately, to patients. However, PAH still carries a high mortality rate, which emphasises the urgent need for transformative innovations in the field. In this Series paper, written by a group of clinicians, researchers, and a patient with PAH, we review therapeutic approaches and treatment options for PAH. We summarise current knowledge of the cellular and molecular mechanisms of PAH, with an emphasis on emerging treatable pathways and optimisation of current management strategies. In considering future directions for the field, our ambition is to identify therapies with the potential to stall or reverse pulmonary vascular remodelling. We highlight novel therapeutic approaches, the important role of patients as partners in research, and innovative approaches to PAH clinical trials.
引用
- Humbert M, Sitbon O, Guignabert C, et al. Treatment of pulmonary arterial hypertension: recent progress and a look to the future. Lancet Respir Med. 2023. PMID: 37591298. doi:10.1016/S2213-2600(23)00264-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。